Tokyo Tape
Sign in
← PeptiDream

Quarterly report · Q3

4587.TEDINET S100S80C
Period2023-01-01 → 2023-09-30
Filed2023-11-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥22.5bn2023-01-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥13.1bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥26.9bn2022-01-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥11.2bn2022-01-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥6.2bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥6.8bn2023-01-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥7.7bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income−¥427m2022-01-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥1.2bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax¥4.7bn2023-01-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥5.8bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥6.7bn2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥369m2022-01-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.2bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥3.5bn2023-01-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥4.3bn2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥7.6bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥187m2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥946m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥3.5bn2023-01-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥4.3bn2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income¥7.6bn2022-01-01 → 2022-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥187m2022-01-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥946m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥66.1bnat 2023-09-30Cons.Assets IFRS
Total assets¥63.9bnat 2022-12-31Cons.Assets IFRS
Total assets¥51.3bnat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥28.6bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥31.8bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥37.5bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥32.0bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥24.5bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥25.4bnat 2021-12-31dCons.Equity IFRS
Equity (owners)¥37.5bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥32.0bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥24.5bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥13.6bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥5.2bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥4.6bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.7bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥9.2bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow−¥83m2022-01-01 → 2022-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥1.4bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥1.8bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥27.4bn2022-01-01 → 2022-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥27.0bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥2.9bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥20.8bn2022-01-01 → 2022-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥20.9bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥27.32023-01-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥32.952023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥58.192022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-1.442022-01-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥7.282022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥27.272023-01-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥32.912023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥58.142022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-1.442022-01-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥7.282022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio56.7%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio50.2%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio47.7%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-09-30−¥63m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-09-30−¥63m
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2023-01-01 → 2023-09-30¥10.7bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2023-01-01 → 2023-09-30¥10.7bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2023-01-01 → 2023-09-30¥6.6bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-09-30¥11.9bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-09-30¥11.8bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2023-01-01 → 2023-09-30¥63m
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-09-30¥247m
—segment totalrevenue2023-01-01 → 2023-09-30¥22.6bn
—segment totalrevenue external2023-01-01 → 2023-09-30¥22.5bn
—segment totalrevenue intersegment2023-01-01 → 2023-09-30¥63m
—segment totalsegment profit2023-01-01 → 2023-09-30¥6.8bn
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-09-30−¥8m
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-09-30−¥8m
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥3.6bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥3.6bn
jpcrp040300-q3r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥197m
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥7.6bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥7.6bn
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2022-01-01 → 2022-09-30¥8m
jpcrp040300-q3r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-09-30¥183m
—segment totalrevenue2022-01-01 → 2022-09-30¥11.2bn
—segment totalrevenue external2022-01-01 → 2022-09-30¥11.2bn
—segment totalrevenue intersegment2022-01-01 → 2022-09-30¥8m
—segment totalsegment profit2022-01-01 → 2022-09-30−¥14m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 601
ItemContextValueUnit
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration304372000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YTDDuration-7183786000JPY
Net increase decrease in cash and cash equivalents IFRSCurrentYTDDuration8323155000JPY
Cash and cash equivalents IFRSPrior2YearInstant11746529000JPY
Cash and cash equivalents IFRSPrior1YearInstant5247665000JPY
Cash and cash equivalents IFRSPrior1QuarterInstant4562743000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant13570821000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q3r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember3569822000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q3r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember7638717000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReportableSegmentsMember11208540000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSPrior1YTDDuration11208540000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember8332000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReportableSegmentsMember8332000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-8332000JPY
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember3569822000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember7647049000JPY
Revenue IFRSPrior1YTDDuration_ReportableSegmentsMember11216872000JPY
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-8332000JPY
Revenue IFRSPrior1YTDDuration11208540000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q3r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember-196580000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q3r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember182930000JPY
Segment profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember-13649000JPY
Segment profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Segment profit loss IFRSPrior1YTDDuration-13649000JPY
Business combination related expenses IFRSPrior1YTDDuration413122000JPY
Operating profit loss IFRSPrior1YTDDuration-426772000JPY
Finance income IFRSPrior1YTDDuration320426000JPY
Finance costs IFRSPrior1YTDDuration129168000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration-132986000JPY
Profit loss before tax IFRSPrior1YTDDuration-368500000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q3r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember10721322000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q3r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember11822628000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReportableSegmentsMember22543951000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSCurrentYTDDuration22543951000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember62820000JPY
Intersegment revenue IFRSCurrentYTDDuration_ReportableSegmentsMember62820000JPY
Intersegment revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-62820000JPY
Intersegment revenue IFRSCurrentYTDDuration－JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember10721322000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember11885448000JPY
Revenue IFRSCurrentYTDDuration_ReportableSegmentsMember22606771000JPY
Revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-62820000JPY
Revenue IFRSCurrentYTDDuration22543951000JPY
Segment profit loss IFRSCurrentYTDDuration_jpcrp040300-q3r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember6573586000JPY
Segment profit loss IFRSCurrentYTDDuration_jpcrp040300-q3r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember246760000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-12-31pass rounding
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass